~EROWID~

triglyceride reduction lipitor

pharms directory

Omthera Pharmaceuticals, Inc. Closes a $6.5M Series A led by ...

Experts dyslipidemia Jerry Wisler and Michael Davidson, MD Co-Found Pharmacists New Theater troupe Develop instruction Omega 3 Treatment of triglycerides Outrageous

NEW YORK - (Charge WIRE) - March 8, 2010 - Omthera Pharmaceuticals, Inc., a specialty pharmaceutical new South African company under private law with an emphasis on expanding clinical dyslipidemia therapies, today announced commencement operations in Bedminster, New Jersey.Perspective artifact mislead Omthera's, Epanova â„¢, an omega-3 containing an unusual formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has yielded favorable results in lowering triglycerides in previous clinical trials, and a unique haven of tolerance and make a bundle. The headset includes Omthera increment dope and marketing excellent Jerry Wisler, President and Chief Senior police officer and a cardiologist and clinical introduced Michael Davidson, MD, Surgeon tec.

"Under the command of Mr. Wisler and Dr.Davidson, Omthera Pharmaceuticals is master of itself to raise the treatment of dyslipidemia, starting with the basic products of Epanova guidance for the treatment of triglycerides very drunk, "said Graziano Seghezzi, Fellow of the game's Omthera table of directors and Friend of Sofinnova Partners, an unparalleled fine diving unshakeable European who led the initial funding for Omthera. "Dr. Davidson clinical knowledge in treating cardio-vascular infection with M.Wisler set of search marketing of cardiovascular therapies are pirate Omthera yield new and innovative therapies for patients who lack them. "

Jerry Wisler brings 25 years of exposure to pharmaceutical Omthera agitation, including the r cooler as co-miscarriage, president and CEO of Aegerion Pharmaceuticals, Inc., a biopharmaceutical crowd focused on progress and commercialization of pharmaceutical products relations with dyslipidemia. During his stay in Aegerion he participated actively entangled in the clinical model of judicial procedure, fundraising, improving business and run-of-the-mill government.In his ex-r Aegerion, Mr. Wisler has been president of marketing for Novartis spot. Mr. Wisler held numerous positions during his 20 years with Merck, including vice president of marketing responsibility for the frankness of atherosclerosis. He has led Merck Zocor ® body during an interval of improvement husky, with annual growth of 1.8 billion dollars in 1997 to $ 5.3 billion in 2002. Mr. Wisler also complex activities in various life cycle director for Zocor, providing commercial input in the regulation to come into a dump Endanger with Schering-cultivation for Zetia and Vytorin ® ®....

Read more...

Comparative Efficacy and Safety of Low-Dose Pitavastatin Versus ...

Training: history studies have shown conflicting results on the cholesterol of low density lipoprotein (LDL-C) reduction comparable doses of pitavastatin and atorvastatin. Dispassionate: Approaching the effectiveness of pitavastatin 1 mg once not always that of atorvastatin 10 mg once daily on the substitution of lipoproteins, the sanctuary, and expenditure per percent reduction in LDL - C. METHODS: An 8-week, randomized, expose brand, try contemporary has been conducted in patients with hypercholesterolemia.One hundred patients were randomized equally to walk off pitavastatin 1 mg once daily or atorvastatin 10 mg once daily, 98 completed the meditation. The results were evaluated at baseline and at the end of the course. RESULTS: pitavastatin lowered LDL-C from baseline by 37% compared to 46% in the class of atorvastatin (p <0.001). Lowering cholesterol complete (TC) levels from baseline was significantly further between pitavastatin (28%) and atorvastatin (32%) groups (p = 0.005).There was no remarkable feature of the percentage changes in triglycerides and the elderly, cholesterol lipoprotein density between the groups. The track of patients who achieved the LDL-C as a function of resident Cholesterol Course curriculum-Mature Treatment Panel III guidelines was not significantly conflict between pitavastatin (74%) and atorvastatin (84%) groups (p = 0.220). In addition, both treatments were well tolerated, without developing a true eminence over 3 times the limit sane highest alanine aminotransferase or 10 times that of creatine kinase.The monthly fee per percent reduction in LDL-C in the heap pitavastatin ($ 0.77) was approximately 50% higher than the costs of degradation in atorvastatin ($ 1.56) aggregation. CONCLUSIONS: Although pitavastatin 1 mg is not usually that shit to lower LDL-C and TC levels as atorvastatin 10 mg per day after day, the company of patients reach their goals of LDL-C with pitavastatin was comparable to the ToT using atorvastatin....

Read more...